| 1 |
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) [J]. JAMA, 2016, 315(8): 801-810.
|
| 2 |
Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis [J]. JAMA, 2019, 321(20): 2003-2017.
|
| 3 |
Kahn JM, Le T, Angus DC, et al. The epidemiology of chronic critical illness in the United States [J]. Crit Care Med, 2015, 43(2): 282-287.
|
| 4 |
Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU [J]. Semin Respir Crit Care Med, 2011, 32(5): 569-580.
|
| 5 |
Cohen J, Opal S, Calandra T. Sepsis studies need new direction [J]. Lancet Infect Dis, 2012, 12(7): 503-505.
|
| 6 |
Angus DC. The search for effective therapy for sepsis: back to the drawing board? [J]. JAMA, 2011, 306(23): 2614-2615.
|
| 7 |
Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process [J]. Chest, 1997, 112(1): 235-243.
|
| 8 |
Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure [J]. JAMA, 2011, 306(23): 2594-2605.
|
| 9 |
Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? [J]. J Clin Invest, 2016, 126(1): 23-31.
|
| 10 |
Wang H, Zhu S, Zhou R, et al. Therapeutic potential of HMGB1-targeting agents in sepsis [J]. Expert Rev Mol Med, 2008, 10: e32.
|
| 11 |
Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? [J]. Virulence, 2014, 5(1): 45-56.
|
| 12 |
Beura LK, Hamilton SE, Bi K, et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice [J]. Nature, 2016, 532(7600): 512-516.
|
| 13 |
Xie J, Chen CW, Sun Y, et al. Increased attrition of memory T cells during sepsis requires 2B4 [J]. JCI Insight, 2019, 4(9): e126030.
|
| 14 |
Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine [J]. Immunol Rev, 2008, 226: 205-218.
|
| 15 |
Tatura R, Zeschnigk M, Hansen W, et al. Relevance of Foxp3+ regulatory T cells for early and late phases of murine sepsis [J]. Immunology, 2015, 146(1): 144-156.
|
| 16 |
Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, et al. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis [J]. Crit Care, 2012, 16(3): R112.
|
| 17 |
Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure [J]. J Immunol, 2005, 174(6): 3765-3772.
|
| 18 |
Toti P, De Felice C, Occhini R, et al. Spleen depletion in neonatal sepsis and chorioamnionitis [J]. AMER J Clin Pathol, 2004, 122(5): 765-771.
|
| 19 |
Chang KC, Unsinger J, Davis CG, et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis [J]. FASEB J, 2007, 21(3): 708-719.
|
| 20 |
Leng FY, Liu JL, Liu ZJ, et al. Increased proportion of CD4+ CD25+ Foxp3+ regulatory T cells during early-stage sepsis in ICU patients [J]. J Microbiol Immunol Infect, 2013, 46(5): 338-344.
|
| 21 |
Venet F, Chung CS, Kherouf H, et al. Increased circulating regulatory T cells (CD4+ CD25+ CD127-) contribute to lymphocyte anergy in septic shock patients [J]. Intensive Care Med, 2009, 35(4): 678-686.
|
| 22 |
Venet F, Chung CS, Monneret G, et al. Regulatory T cell populations in sepsis and trauma [J]. J Leukoc Biol, 2008, 83(3): 523-535.
|
| 23 |
Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis [J]. J Exp Med, 2007, 204(6): 1463-1474.
|
| 24 |
Barnstorf I, Borsa M, Baumann N, et al. Chronic virus infection compromises memory bystander T cell function in an IL-6/STAT1-dependent manner [J]. J Exp Med, 2019, 216(3): 571-586.
|
| 25 |
Regis G, Icardi L, Conti L, et al. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing [J]. Leukemia, 2009, 23(11): 2102-2108.
|
| 26 |
Jimbo A, Fujita E, Kouroku Y, et al. ER stress induces caspase-8 activation, stimulating cytochrome c release and caspase-9 activation [J]. Exp Cell Res, 2003, 283(2): 156-166.
|
| 27 |
Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion [J]. Immunology, 2010, 129(4): 474-481.
|
| 28 |
Hein F, Massin F, Cravoisy-Popovic A, et al. The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states [J]. Crit Care, 2010, 14(1): R19.
|
| 29 |
Scumpia PO, Delano MJ, Kelly KM, et al. Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis [J]. J Immunol, 2006, 177(11): 7943-7949.
|
| 30 |
Kuhlhorn F, Rath M, Schmoeckel K, et al. Foxp3+ regulatory T cells are required for recovery from severe sepsis [J]. PLoS One, 2013, 8(5): e65109.
|
| 31 |
Angus DC, van der Poll T. Severe sepsis and septic shock [J]. N Engl J Med, 2013, 369(9): 840-851.
|
| 32 |
Efron PA, Mohr AM, Moore FA, et al. The future of murine sepsis and trauma research models [J]. J Leukoc Biol, 2015, 98(6): 945-952.
|
| 33 |
Lewis AJ, Rosengart MR. Bench-to-bedside: a translational perspective on murine models of sepsis [J]. Surg Infect (Larchmt), 2018, 19(2): 137-141.
|
| 34 |
Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease [J]. N Engl J Med, 2014, 371(4): 380-383.
|
| 35 |
Brahmamdam P, Inoue S, Unsinger J, et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis [J]. J Leukoc Biol, 2010, 88(2): 233-240.
|
| 36 |
Patera AC, Drewry AM, Chang K, et al. Frontline science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1 [J]. J Leukoc Biol, 2016, 100(6): 1239-1254.
|
| 37 |
Chang KC, Burnham CA, Compton SM, et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis [J]. Crit Care, 2013, 17(3): R85.
|
| 38 |
Nalos M, Santner-Nanan B, Parnell G, et al. Immune effects of inter-feron gamma in persistent staphylococcal sepsis [J]. Am J Respir Crit Care Med, 2012, 185(1): 110-112.
|
| 39 |
Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation [J]. Blood, 2012, 120(24): 4882-4891.
|
| 40 |
Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis [J]. J Immunol, 2010, 184(7): 3768-3779.
|
| 41 |
Wesche-Soldato DE, Swan RZ, Chung CS, et al. The apoptotic pathway as a therapeutic target in sepsis [J]. Curr Drug Targets, 2007, 8(4): 493-500.
|